Alberta Investment Management Corp Increases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Alberta Investment Management Corp increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 25.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,900 shares of the company's stock after buying an additional 2,200 shares during the period. Alberta Investment Management Corp's holdings in IDEXX Laboratories were worth $4,506,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Whittier Trust Co. raised its holdings in shares of IDEXX Laboratories by 10.1% in the 3rd quarter. Whittier Trust Co. now owns 1,673 shares of the company's stock valued at $845,000 after acquiring an additional 153 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its position in shares of IDEXX Laboratories by 6.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 809 shares of the company's stock worth $409,000 after purchasing an additional 48 shares during the last quarter. Eastern Bank bought a new position in shares of IDEXX Laboratories in the third quarter worth approximately $90,000. GAM Holding AG raised its stake in IDEXX Laboratories by 2.9% in the third quarter. GAM Holding AG now owns 5,033 shares of the company's stock valued at $2,543,000 after purchasing an additional 140 shares in the last quarter. Finally, Lecap Asset Management Ltd. bought a new stake in IDEXX Laboratories during the third quarter valued at approximately $419,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IDXX has been the topic of a number of research analyst reports. Leerink Partners began coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price target on the stock. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, February 5th. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Finally, Piper Sandler raised their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $533.75.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sophie V. Vandebroek sold 344 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now owns 905 shares in the company, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 13,330 shares of company stock valued at $6,161,276 over the last three months. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Trading Up 0.4 %

IDEXX Laboratories stock traded up $1.90 during trading hours on Thursday, reaching $452.89. The company had a trading volume of 615,712 shares, compared to its average volume of 704,594. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The company has a 50-day moving average price of $431.19 and a 200 day moving average price of $452.42. The firm has a market cap of $37.09 billion, a price-to-earnings ratio of 42.45, a P/E/G ratio of 3.38 and a beta of 1.37.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.